Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 7/20 | 0.49 |
| ▸ | ESRRB | O95718 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESRRG | P62508 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.44 |
| ▸ | VHL | P40337 | 1/20 | 0.39 |
| ▸ | BAG3 | O95817 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4405009 | 1.00 | ESRRA (0.49) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL4404915 | 0.93 | ESRRA (0.48) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL647234 | 0.91 | ESRRA (0.50) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL647235 | 0.91 | ESRRA (0.50) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL651256 | 0.90 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648909 | 0.90 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648910 | 0.90 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL650091 | 0.90 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648125 | 0.89 | ESRRA (0.63) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648126 | 0.89 | ESRRA (0.63) | ESRRAESRRBESR1ESRRGESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108571-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | GAUL MICHAEL (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108571-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.